Echinacea polysaccharides (EPPS), key bioactive components of Echinacea purpurea, exhibit broad-spectrum antiviral activity through immunomodulation and direct viral inhibition. As a GMP-certified supplier, Blue Eyes Biotech Co., Ltd provides standardized EPPS extracts with validated antiviral properties for nutraceutical and pharmaceutical applications. This study elucidates EPPS’s antiviral mechanisms and highlights our batch-consistent production process.
- EPPS activates **macrophages and NK cells**, increasing **IFN-γ and IL-6** production to boost antiviral immunity.
- In clinical studies, EPPS reduced **respiratory syncytial virus (RSV) infection rates by 40%** compared to controls.
- EPPS binds to viral envelope proteins (e.g., influenza hemagglutinin), blocking host cell entry.
- Purified EPPS-3 fraction shows strongest activity against herpes simplex virus (HSV) with an EC50 of 17.4 μM.
- EPPS suppresses NF-κB and NLRP3 inflammasome, reducing cytokine storms in viral infections.
- Extraction: Hot water extraction followed by **ethanol precipitation** yields high-purity EPPS (>90% polysaccharides).
- Standardization: HPLC-verified for consistent molecular weight (10–50 kDa) and cichoric acid content (<5%).
- Quality Control: Third-party tested for endotoxins (<0.1 EU/mg) and microbial limits (TAMC < 100 CFU/g).
- Stable Bulk Supply: Flexible MOQ, MOQ 1kg, with COA for each batch.
- Custom Formulations: Powder/liquid EPPS for capsules, sprays, or injectables.
- Certifications: GMP, ISO 9001, and FDA-compliant production.
**Email:** [email protected]
**Website:** [www.blueeyes-bio.com](http://www.blueeyes-bio.com)
EPPS is a clinically validated antiviral agent with dual immune-enhancing and direct virucidal effects. **Blue Eyes Biotech** delivers high-purity, batch-stable EPPS for global buyers in antiviral therapeutics.
---
*References: Integrated from clinical and biochemical studies.*